India, March 28 -- Liquidia Corp. (LQDA), a biopharmaceutical company focused on developing treatments for rare cardiopulmonary diseases, announced Friday that the U.S. Food and Drug Administration has accepted its New Drug Application or NDA resubmission for Yutrepia - treprostinil inhalation powder.
Yutrepia is intended for patients with pulmonary arterial hypertension, and pulmonary hypertension associated with interstitial lung disease. The company said FDA had confirmed that the resubmission is a complete, Class 1 response to the previous action letter dated August 16, 2024, which had granted tentative approval for the drug. The agency has set a Prescription Drug User Fee Act - PDUFA goal date of May 24, 2025.
Liquidia's Chief Execut...